Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX followed by local therapy in locally advanced pancreatic cancer (Nordic phase II)
2017-003775-62Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- Mar 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, irinotecan and oxaliplatin in pancreatic cancer (PC), sponsored by University Hospital Odense. Primary endpoint: 2-year overall survival from start of chemotherapy. Started Mar 2018; status: completed.
02
Drugs
fluorouracilirinotecanoxaliplatin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2017-003775-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003775-62.